Navigation Links
Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
Date:12/2/2010

y to E. coli-derived proteins, such as filgrastim.

Serious allergic reactions, including anaphylaxis, can occur in patients receiving Neulasta or NEUPOGEN. Permanently discontinue Neulasta or NEUPOGEN in patients with serious allergic reactions.

Splenic rupture, including fatal cases, can occur following the administration of Neulasta and NEUPOGEN.

Acute respiratory distress syndrome (ARDS) can occur in patients receiving Neulasta or NEUPOGEN.

Alveolar hemorrhage, manifesting as pulmonary infiltrates and hemoptysis requiring hospitalization, has been reported in healthy donors undergoing peripheral blood progenitor cell mobilization, an unapproved use of NEUPOGEN. Hemoptysis resolved with discontinuation of NEUPOGEN.

Bone pain and pain in extremity occurred at a higher incidence in Neulasta-treated patients as compared with placebo-treated patients. In clinical trials involving NEUPOGEN, bone pain was most frequently reported adverse event.

Important European Product Safety InformationFor full prescribing information please see the Summary of Product Characteristics for each product.

NEUPOGEN is indicated for reduction in duration of neutropenia and incidence of febrile neutropenia after established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes); reduction in duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of NEUPOGEN are similar in adults and children receiving cytotoxic chemotherapy. NEUPOGEN is indicated for mobilisation of peripheral blood progenitor cells (PBPCs); long-term treatment to increase neutrophil counts and reduce incidence and duration of infection-related events in patients with severe congenital, cyclic, or idiopathic neutropenia treatment of persistent neutropenia in patients
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
2. Choices
3. Empowerment Competition
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
6. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
7. Amgen Announces Webcast of 2010 Third Quarter Financial Results
8. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
9. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
10. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
11. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANCISCO , Aug. 27, 2015  QB3@953—a ... by QB3, a University of California (UC) research ... with pharmaceutical company GSK to identify and facilitate ... medicines that benefit patients. The agreement ... Partnerships with Academia (DPAc) team and creates a ...
(Date:8/27/2015)... CAMBRIDGE, Mass. , Aug. 27, 2015 /PRNewswire/ ... the Rodman & Renshaw 17th Annual Global Investment Conference in ... St. Regis Hotel, ORYZON will be represented by President and ... Dr. Buesa will present this information on ... Fontainebleau Room (2nd Floor).  The company is completing preclinical development ...
(Date:8/26/2015)... August 27, 2015 ... the genotyping technology, its application and products ... nucleotide polymorphism (SNP) genotyping industry analysis are ... report on genotyping market by technology, application ... profiling 10 major companies and supported with ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 3Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 5
... , May 14 Medco Health Solutions, Inc., (NYSE: ... donated $125,000 to the U.S. Red Cross for relief efforts targeted ... , , , ... largest pharmacies and parent company of Memphis -based Accredo Health Group -- ...
... , May 14 Hospira, Inc. ... specialty pharmaceutical and medication delivery company, will expand its ... to its portfolio of non-DEHP intravenous (I.V.) administration sets. ... increased customer efficiency and reduced impact on the environment, ...
Cached Medicine Technology:Medco Donates $125,000 to Red Cross for Flood Relief in Tennessee and Other Affected Areas 2Medco Donates $125,000 to Red Cross for Flood Relief in Tennessee and Other Affected Areas 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 4
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some patients ... later, relapsing and returning again, all at great cost to them and their families. ... homes or soon after leaving facilities who claim to have given addicts tools to ...
(Date:8/27/2015)... ... August 27, 2015 , ... In an article published July ... the city of New Orleans, highlighting a security firm that is tasked with providing ... tech oriented entrepreneur who worked with the city to provide private security when it ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent ... into the Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands ... Georgia State University study. , While most people don’t develop persistent depression after ...
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
Breaking Medicine News(10 mins):Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4
... , , BATESVILLE, ... and Radianse today announced a strategic partnership agreement to integrate ... Nurse Call system. With this move, Hill-Rom intends to ... to remove financial and technical obstacles for health care customers ...
... NOVATO, Calif., Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Financial Officer of BioMarin, will present a company update at the Thomas ... 4:25 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SOMERSET, N.J., Sept. 2 ... US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine ... of seasonal and perennial allergic rhinitis (SAR and PAR). ... to offer convenient once-daily dosing for patients who suffer from ...
... BEIJING, Sept. 2 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; ... Xinhua News Agency publicized the creation of "Opinions of the,CPC ... of the,Medical and Health Care System" ("Opinion"). , ... to go see a,doctor more easily. Reduced cost is the ...
... , , , ... 2 /PRNewswire-FirstCall/ -- DUSA ... is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products ... President and Chief Executive Officer, will present a corporate overview at ...
... , , SAN JOSE, Calif., ... device company, today announced that its IsoFlow (TM) ... and Drug Administration (FDA) for the direct delivery of medications into ... the treatment of cancer. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090902/SF69552 ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 2Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4
... ABI Prism 7000 Sequence Detection System ... that detects and quantitates nulceic acid ... of accumulated PCR product is made ... detection, and application-specific software in a ...
... system offers continuous, unattended operation with ... and detection, and data analysis. After ... importing sample information, the operator needs ... command. The instrument requires no further ...
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
RIA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
Medicine Products: